BioStock: Chordate Medical resumes initiative with Nanos Medical in China

Chordate Medical is making progress in China with K.O.S. rhinitis treatment. The company has received a prepaid order for two new-generation K.O.S. devices from Changyong Medical Technology, the joint venture company co-owned with Nanos Medical in Shanghai. The market registration process in China has resumed and a new joint venture agreement is being negotiated with Nanos Medical. BioStock had the opportunity to talk to Nanos Medical’s CEO Terry Cui about the collaboration with Chordate Medical and the potential in China for K.O.S.

Read the full interview at biostock.se: 

https://www.biostock.se/en/2021/09/chordate-medical-resumes-initiative-with-nanos-medical-in-china/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se